Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

ConclusionsFOLFIRI  + S has signs of clinical activity in patients with advanced gastric and GEJ adenocarcinoma, and the side-effect profile was similar to previously reported studies. Current treatment paradigms in gastric cancer probably negate further study of this regimen.ClinicalTrials.gov identifier: NCT00524186.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research